Phase 3 · Research guide
Retatrutide Phase 3 Research Guide
Updated October 20, 2026: added the published papers' numbers.
Every published trial, every dose, and what the data says about running it well.
Retatrutide's phase 3 results were published in September 2026, TRIUMPH-1 in NEJM and TRIUMPH-2 in The Lancet. This card puts the trial titration and results by dose in one place.
01 / TITRATION
How the trials titrated
STEP 01
2mg
weeks 1-4
20 units
STEP 02
4mg
weeks 5-8
40 units
STEP 03
6mg
weeks 9-12
60 units
STEP 04
9mg
weeks 13-16
90 units
STEP 05
12mg
week 17 onward
120* units
Every arm started at 2mg once weekly and stepped up every four weeks. Nobody in the 12mg group reached 12mg until around week 17. Lower-dose arms stopped climbing at their target (4mg or 9mg).
Units assume 10 mg per mL on a U-100 insulin syringe. 2 mg was only ever a starting step. No trial kept anyone on 2 mg, so there's no 2 mg result.
02 / STARTING DOSE
Start at 2 mg. The trials tested what happens if you don't.
Nausea · titrating to 8 mg (phase 2)
17%
started at 2 mg
60%
started at 4 mg
Vomiting · titrating to 8 mg (phase 2)
6%
started at 2 mg
26%
started at 4 mg
Same target dose, same drug. Starting one step higher roughly tripled nausea. In the 4 mg arms it doubled, 18% versus 36%. Most side effects clustered during dose increases, which is why the four-week holds exist.
03 / RESULTS
Weight loss by dose at 80 weeks
| Dose | TRIUMPH-1 if they stayed on it | TRIUMPH-1 counting everyone who started | TRIUMPH-2 if they stayed on it | TRIUMPH-2 counting everyone who started |
|---|---|---|---|---|
| 4mg | 19.0% | 17.6% | 12.7% | 11.9% |
| 9mg | 25.9% | 23.7% | 19.1% | 16.8% |
| 12mg | 28.3% | 25.0% | 20.8% | 18.8% |
| Placebo | 2.2% | 3.9% | 4.0% | 5.1% |
Lilly's releases lead with the number for people who stayed on the drug (the efficacy estimand). The NEJM and Lancet papers lead with the number for everyone who started, including people who stopped (the treatment-regimen estimand).
If you're insulin resistant, prediabetic or diabetic, TRIUMPH-2 is the trial that describes you. In the diabetic trial, going from 9mg to 12mg added only 1.7 points (2.0 counting everyone who started).
In TRIUMPH-1, 45.3% of the 12 mg group lost 30% or more of their body weight.
04 / TIMING
When the weight comes off
Weeks 24 and 48 from the phase 2 trial, week 80 from TRIUMPH-1. The 12 mg curve was still dropping at week 48 with no plateau. Judge it at months, not weeks: the first 16 weeks are mostly titration.
05 / TRIALS
Every trial so far, at the top dose
| Trial | Who was in it | People | Length | If they stayed on it | Counting everyone who started |
|---|---|---|---|---|---|
| Phase 2 | Obesity | 338 | 48 weeks | 24.2% | — |
| TRIUMPH-1 | Obesity, no diabetes | 2,339 | 80 weeks | 28.3% | 25.0% |
| TRIUMPH-2 | Obesity + type 2 diabetes | 1,152 | 80 weeks | 20.8% | 18.8% |
| TRIUMPH-3 | Severe obesity + heart disease | 1,949 | 80 weeks | 22.6% | — |
| TRIUMPH-4 | Obesity + knee osteoarthritis | 445 | 68 weeks | 28.7% | 23.7% |
06 / SAFETY
Side effects, by the numbers
11-18%
quit the 12 mg dose over side effects. 11.3% in TRIUMPH-1, 18.2% in TRIUMPH-4. Placebo was 4-5%.
7-21%
dysesthesia at 12 mg, an altered skin sensation unique to this drug. 7.3% in TRIUMPH-2, 20.9% in TRIUMPH-4.
+6.7
beats per minute peak resting heart rate rise at 12 mg in phase 2, highest around week 24, easing after.
GI effects (nausea, vomiting, diarrhea, constipation) were the most common, mostly mild to moderate, and concentrated during dose increases. Lower doses dropped out less: 4.1% at 4 mg in TRIUMPH-1, below placebo.
07 / CONCENTRATION
Reconstitution math
10 mg vial + 1 mL bacteriostatic water = 10 mg per mL. On a U-100 insulin syringe, 10 units = 1 mg. Same concentration with 20 mg + 2 mL or 30 mg + 3 mL.
| Dose | U-100 syringe units at 10 mg per mL |
|---|---|
| 2 mg | 20 units |
| 4 mg | 40 units |
| 6 mg | 60 units |
| 9 mg | 90 units |
| 12 mg | 120 units* |
*120 units is more than a 1 mL syringe holds, and more than one 10 mg vial contains. At the 12 mg step, a stronger mix avoids splitting: 30 mg vial + 2 mL = 15 mg per mL, so 12 mg = 80 units. Recheck the math every time you change vial size or water volume.
08 / MONITORING
What's worth tracking
- Body weight and waist, weekly
- Resting heart rate, weekly
- A1C and fasting glucose
- Lipid panel
- CMP (kidney and liver)
- Lipase
Get a baseline before starting, then recheck around every three months. Weight, waist, A1C, glucose, blood pressure and lipids are the markers the trials themselves reported.
09 / STATUS
Where it stands
Now
not approved in any country
Q1 2027
Lilly files the BLA with the FDA
+10-12 months
standard FDA review
Late 2027
earliest realistic approval
Unlock the full card
Two-page research guide. Results by dose, side effects, reconstitution math and what to track. Free.
No spam, unsubscribe anytime
For research and educational purposes only. Retatrutide is investigational and not approved for human use in any jurisdiction. Not medical advice.